Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

San Cugat del Valles, Spain Clinical Trials

A listing of San Cugat del Valles, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (238) clinical trials

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.

Phase

4.2 miles

Learn More »

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Chemotherapy-nave patients high-intermediate TMB (TMB10 mutations/MB) and with locally advanced or metastatic non-squamous non-small cell lung cancer patients will be selected. Enroled patientswill receive 1200 mg of atezolizumab and 15mg/Kg of Avastin (bevacizumab) administered by IV infusion every 21 days (+/- 3 days). The treatment will start within 1-5 days ...

Phase

4.2 miles

Learn More »

Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients

This is an international, prospective, open-label, multicenter, single arm, two-stage Simon Design phase II clinical trial, with the primary objective of assessing the efficacy of nal-IRI single agent in a cohort of HER2-negative metastatic breast cancer (MBC) patients with CNS involvement. Eligible patients will have histologically proven diagnosis of adenocarcinoma ...

Phase

4.46 miles

Learn More »

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

The primary goal of this trial is to assess the activity, safety, and tolerability of tisotumab vedotin for the treatment of selected solid tumors. Patients will be treated with single agent tisotumab vedotin. Patients who meet eligibility criteria will be enrolled into cohorts based on tumor type. Tumor types to ...

Phase

4.46 miles

Learn More »

Study of Vinblastine in Combination With Nilotinib in Children Adolescents and Young Adults

Low grade gliomas (LGG) are the most frequent brain tumor type in children. They are often chemosensitive. However, more than 50% of these tumors will progress within the first 5 years after the start of the treatment and need a second-line therapy. In most cases, patients are still young and ...

Phase

4.97 miles

Learn More »

XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

The purpose of this study is to determine the pathological complete response rate of addition of bevacizumab to induction therapy (xelox) and concomitant treatment (capecitabine+radiotherapy), followed by surgery.

Phase

5.08 miles

Learn More »

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.

Phase

5.08 miles

Learn More »

ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active Moderate to Severe Graves' Ophthalmopathy ( GO )

The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO patients. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG

Phase

5.08 miles

Learn More »

Study To Evaluate the Efficacy Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies

This study will be conducted to compare E2027 to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus (CIBIC-Plus) Caregiver Input in participants with dementia with Lewy bodies after 12 weeks of treatment.

Phase

5.22 miles

Learn More »

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

This clinical study is designed to evaluate the pharmacokinetics, safety and efficacy of ligelizumab in children from 12 to <18 years of age, with chronic spontaneous urticaria. The study will generate data to be analyzed in a separate modelling and simulation study with the objective of i) estimating the relative ...

Phase

5.22 miles

Learn More »